Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
By
[email protected] (Brendan Coffey)
2d agoen
Source
BarsEli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?fool.comGrowth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
You might also wanna read
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years
Barchart·19h ago
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
24/7 Wall St.·3h ago
This $1,200 Stock Could Be the Next Massive Stock Split Opportunity
24/7 Wall St.·6h ago
JEPI vs. JEPQ: Which Is the Better Buy in July?
24/7 Wall St.·3h ago
Eli Lilly Revenue Surges 55.5% on Mounjaro Sales, But Stock Lags Amid Pricing Pressures
Eli Lilly reported strong Q1 results with 55.5% revenue growth to $19.80 billion, driven by Mounjaro's $8.66 billion in sales. The company r
briefly.co·18d ago
Bernstein says the future of tech is quantum. These two stocks have the most upside
cnbc.com·29d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.